Floatz logo

HU-GM-CSF

Depressive Disorder, Major

Shanghai Mental Health Centerprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Depressive Disorder, Major cohort.

Asset / SponsorPhaseRating
Amitriptyline
Janssen Research & Development, LLC
Phase 4BBB
Pregabalin
Janssen Research & Development, LLC
Phase 4BBB
((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST
Janssen Research & Development, LLC
Phase 3BB
Lorazepam
Mclean Hospital
Phase 4BB
Acamprosate
Hanyang University Seoul Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

HU-GM-CSF is also rated in:

amyotrophic lateral sclerosisDormant
B
Indicative ·
63 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
57 / 100
View asset →
Advanced and Relapsed Solid TumorsDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →